Loic Ysebaert
IUCT Oncopole de Toulouse
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Loic Ysebaert as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:53 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT02889523 · Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by ChemiotherapyThe Lymphoma Academic Research Organisation · active not recruiting · Lymphoma, DLBCL, Follicular Lymphoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:53 UTC. The ranking covers the 200 most relevant of 36 PubMed records, and a shared surname and initials can bring in a namesake. All 36 on PubMed
- 324 citationsRCR 9.2
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.N Engl J Med · 2018309 citationsRCR 10.4
- Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.Lancet Oncol · 2013256 citationsRCR 7.4
- Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.J Clin Oncol · 2019241 citationsRCR 9.2
- Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.NEJM Evid · 2022216 citationsRCR 15.2
- Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.Blood · 2017184 citationsRCR 5.5
- Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).J Clin Oncol · 2022178 citationsRCR 11.4
- Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.Lancet Haematol · 2017173 citationsRCR 5.5
- 141 citationsRCR 12.6
- 135 citationsRCR 3.2